GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Shares Outstanding (EOP)

Clover Biopharmaceuticals (HKSE:02197) Shares Outstanding (EOP) : 1,296.29 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Clover Biopharmaceuticals's shares outstanding for the quarter that ended in Dec. 2023 was 1,296.29 Mil.

Clover Biopharmaceuticals's quarterly shares outstanding increased from Jun. 2023 (1,294.00 Mil) to Dec. 2023 (1,296.29 Mil). It means Clover Biopharmaceuticals issued new shares from Jun. 2023 to Dec. 2023 .

Clover Biopharmaceuticals's annual shares outstanding increased from Dec. 2022 (1,292.64 Mil) to Dec. 2023 (1,296.29 Mil). It means Clover Biopharmaceuticals issued new shares from Dec. 2022 to Dec. 2023 .


Clover Biopharmaceuticals Shares Outstanding (EOP) Historical Data

The historical data trend for Clover Biopharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals Shares Outstanding (EOP) Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
1,158.12 1,158.12 1,158.11 1,292.64 1,296.29

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial 1,158.11 1,161.22 1,292.64 1,294.00 1,296.29

Competitive Comparison of Clover Biopharmaceuticals's Shares Outstanding (EOP)

For the Biotechnology subindustry, Clover Biopharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clover Biopharmaceuticals's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's Shares Outstanding (EOP) falls into.



Clover Biopharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Clover Biopharmaceuticals  (HKSE:02197) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Clover Biopharmaceuticals Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Clover Biopharmaceuticals (HKSE:02197) Business Description

Traded in Other Exchanges
N/A
Address
1598-1601 West Nanjing Road, 49th Floor, Park Place, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.
Executives
Liang Peng 2101 Beneficial owner
Liang Joshua G 2501 Other
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Aut-xxi Investment Holdings Limited 2201 Interest of corporation controlled by you
Jnry V Holdings Limited 2101 Beneficial owner
Aut-xxi Hk Holdings Limited 2101 Beneficial owner
Aut-xxi Holdings Limited 2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Super Novel International Limited 2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals (HKSE:02197) Headlines

No Headlines